NEW YORK, April 29, 2014 /PRNewswire/ -- IntelliCell
BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a
regenerative medicine company utilizing adult autologous Stromal
Vascular Cells (SVCs) derived from the blood vessels found in
adipose tissue, announced today that it supplied its Stromal
Vascular Fraction Cells, manufactured using its patented ultrasonic
technology, for the restoration of cardiac function at the
University of Arizona College of
Medicine, Tucson in collaboration
with Dr. Zain Khalpey, Division of Cardiothoracic Surgery. The
autologous cells were gathered on site with Institutional Review
Board approval in accordance with all applicable regulatory
requirements. The case was reported in Clinical Communication to
the Editor in The American Journal of Medicine Vol.127, No 5,
May 2014.
http://www.amjmed.com/article/S0002-9343(14)00079-5/fulltext
According to Dr. Zain Khalpey's conclusions in the clinical
communications to The American Journal of Medicine, "We postulate
that the intramyocardial administration of multi-potent
adipose-derived stromal vascular fraction cells and their diverse
composition guided engraftment in the damaged area, facilitated the
cardiomyocyte regenerative properties, and helped improve cardiac
function. Because subcutaneous adipose tissue is readily available
in most patients, adipose-derived stromal vascular fraction cells
present a feasible clinical intervention for cardiac dysfunction.
The population complexity, which includes stromal vascular fraction
and growth factors, likely promotes repair by recruiting
cardiomyocytes. The autologous nature and multi-potency of these
cells may contribute to them being ideal for cardiac function
restoration."
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a momentous
point for Intellicell Biosciences illustrating that its Stromal
Vascular Fraction Cells (SVFC) and its technology have clinical
promise in the restoration of cardiac function. I believe Dr.
Khalpey's theory of injecting the SVFCs intracardiac externally and
intravenously under a compassionate IRB, will pave the way for our
FDA IND study that will focus on Congestive Heart Failure. This IND
study will be important for proving the company's patented
technology of Ultrasonic Cavitation as a method of separating
stromal vascular fraction cells from lipoaspirate. We believe that
IntelliCell's Stromal Vascular Fraction Cells injected into the
cardiac muscle externally and given intravenously will make a
significant clinical difference. We at IntelliCell would like to
thank Ms. Stephanie Squicciarini for
flying out to Tucson, Arizona with
our lab and manufacturing the SVFCs in the operating room for Dr.
Khalpey."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using adult
autologous stromal vascular fraction cells (SVFCs) derived from the
blood vessels in the adult adipose tissue. IntelliCell BioSciences
has developed its own patented technology and protocol to separate
adult autologous vascular cells from adipose tissue without the use
of enzymes. IntelliCell will also be seeking to develop
technology-licensing agreements with technology developers,
universities, and international business entities.
About Dr. Zain Khalpey according to the University of Arizona website
Born in Africa, Dr. Khalpey
completed his medical education in the UK and studied and worked
extensively throughout Europe and
the United States before deciding
to pursue his organ transplantation research at the University of Arizona, the birthplace of the Total
Artificial Heart.
In addition to his clinical work at The University of Arizona Medical Center, where he
recently was appointed director of the internationally renowned
heart transplant program and mechanical circulatory support,
Khalpey is involved in numerous research activities, focused mainly
in three key areas: bridge to regeneration, organ reconditioning
and organogenesis, or the creation of new organs.
The first area, bridge to regeneration, focuses on reducing the
number of people who require heart transplants by improving stem
cell treatments for failing hearts.
http://surgery.arizona.edu/faculty-profile/zain-khalpey-md-phd-mrcs
About Arizona College of
Medicine according to website
For more than a decade, The University of
Arizona Medical Center has been ranked among the nation's
best hospitals by U.S. News & World Report.
The University of Arizona Health
Network is Arizona's first
academic medical network. It includes The University of Arizona Medical Center - University
Campus, The University of
Arizona Medical Center - Diamond
Children's, The University of
Arizona Medical Center - South Campus, some 40 clinics,
a health plan division and the practice plan for physicians from
the University of Arizona College of
Medicine. It's been nationally recognized for providing exceptional
patient care, teaching new health care professionals and conducting
groundbreaking research through the physician-scientists of the
University of Arizona College of
Medicine.
https://www.uahealth.com/
Forward-Looking Statements
Certain statements set
forth in this press release constitute "forward-looking
statements." Forward-looking statements include, without
limitation, any statement that may predict, forecast, indicate, or
imply future results, performance or achievements, and may contain
the words "estimate," "project," "intend," "forecast,"
"anticipate," "plan," "planning," "expect," "believe," "will
likely," "will reach," "will change," "will soon," "should,"
"could," "would," "may," "can" or words or expressions of similar
meaning. Such statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause the
company's actual results and financial position to differ
materially from those included within the forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including those relating to the Company's ability to
grow its business. Actual results may differ materially from the
results predicted and reported results should not be considered as
an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited
operating history, the limited financial resources, domestic or
global economic conditions, activities of competitors and the
presence of new or additional competition, and changes in Federal
or State laws. More information about the potential factors that
could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact:
IntelliCell BioSciences, Inc.
Investor Relations
Anna Rhodes
arhodes@intellicellbisciences.com
(646) 576-8308
SOURCE IntelliCell BioSciences, Inc.